Doctrine of Equivalents Checklist: A Practical Checklist

How to use this checklist

A doctrine of equivalents claim survives only if it clears a series of legal gates and then a demanding standard of proof. Most of the gates are for the judge, and most of the answers are in the file history. Work the phases in order, because a failure at an early phase often makes later work unnecessary.

Phases 0 to 4 apply to both sides and should be done before a complaint, an answer, or a response to a notice letter. Phases 5 to 10 are the litigation sequence, with tasks marked [P] for the patent owner, [D] for the accused infringer, or [Both]. Phase 11 is for prosecutors with an application still pending.

Run the analysis separately for each asserted claim, each accused product, and each limitation not literally met. For the doctrine, read The Doctrine of Equivalents and Prosecution History Estoppel: When a Patent Reaches Beyond Its Literal Words. For the narrative with sample language, see Proving or Defeating Infringement Under the Doctrine of Equivalents: A Practical Guide. For templates that match these tasks, see Doctrine of Equivalents Toolkit: Claim Charts, Estoppel Histories, and Ensnarement Analyses.

Bear in mind what the Federal Circuit has said about this doctrine: liability under it is "exceptional," per VLSI Technology LLC v. Intel Corp., 87 F.4th 1332 (Fed. Cir. 2023). It is not a routine second prong of an infringement case.

Phase 0: Frame the question

• Confirm claim construction status. Equivalents analysis starts from the construed claim. Note whether construction is decided, proposed, or uncertain, and run the analysis under each plausible construction. See Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). Note: A bad construction reversed on appeal can reopen equivalents, as in Deere & Co. v. Bush Hog, LLC, 703 F.3d 1349 (Fed. Cir. 2012). For the process, see Claim Construction Checklist: A Practical Checklist.
• List each limitation not literally met, by claim and accused product, with one sentence on the difference. Equivalence is assessed limitation by limitation under Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 520 U.S. 17 (1997). Note: If the list exceeds one or two limitations per claim, reconsider the theory. Multiple equivalents in one claim looks like the whole-invention comparison the cases forbid.
• Confirm the claim is not means-plus-function, or separate the analysis if it is. 35 U.S.C. § 112(f) equivalence is a literal infringement question, measured at issuance, requiring identical function. See Chiuminatta Concrete Concepts, Inc. v. Cardinal Industries, Inc., 145 F.3d 1303 (Fed. Cir. 1998).
• Identify the patent type. Design patents use "colorable imitation" under 35 U.S.C. § 289, and estoppel is measured by surrendered figures. See Pacific Coast Marine Windshields Ltd. v. Malibu Boats, LLC, 739 F.3d 694 (Fed. Cir. 2014).
• Calendar what is coming. Note the contentions deadline, Markman date, expert report dates, and dispositive motion dates under Fed. R. Civ. P. 16. If a notice letter has arrived, see Managing Willfulness Risk After a Patent Notice Letter: A Practical Guide, and for where a suit may land, see Patent Venue and Transfer Checklist: A Practical Checklist.

Phase 1: Collect the record

• Order the certified file history of each asserted patent and all priority applications. Authority for relevance: Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).
• Add family members and post-grant records: continuations, divisionals, continuations-in-part, reissues, reexaminations, inter partes reviews. Note: Estoppel can extend within a lineage but is not automatic. Compare Trading Technologies International, Inc. v. Open E Cry, LLC, 728 F.3d 1309 (Fed. Cir. 2013). IPR statements can support disclaimer under Aylus Networks, Inc. v. Apple Inc., 856 F.3d 1353 (Fed. Cir. 2017).
• Collect the cited references for each rejection, and read what they actually disclose on the accused feature.
• Collect the specification's statements about alternatives to each limitation at issue, including incorporated documents.
• Gather accused product facts at the operational level: drawings, test data, specifications, source code, architecture documents.
• Preserve the design history. If you are the accused infringer, confirm a legal hold covers engineering records on why the accused feature was chosen.

Red flag: A "file history summary" from a vendor or an old opinion letter is not a substitute. The dispositive point in these cases often sits in a canceled claim or a single sentence of remarks.

Phase 2: Prosecution history estoppel

Apply the sequence from Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003) (en banc).

• Did an amendment narrow the literal scope? Include added limitations, and treat rewritten dependents with canceled parents as narrowing under Honeywell International Inc. v. Hamilton Sundstrand Corp., 370 F.3d 1131 (Fed. Cir. 2004) (en banc). Note: A truly cosmetic amendment raises no estoppel. Festo, 535 U.S. at 736-37.
• Check canceled claims on related subject matter. Under Colibri Heart Valve LLC v. Medtronic CoreValve, LLC, No. 23-2153 (Fed. Cir. July 18, 2025), canceling a closely related independent claim can narrow the retained claim, even though the retained claim's words never changed.
• Was the reason related to patentability? Includes §§ 101, 102, 103, and 112. If the record is silent, the Warner-Jenkinson presumption applies, and rebuttal is confined to the record.
• Define the surrendered territory. State the original language, the amended language, and everything between.
• Place the accused feature. Is it inside that territory? Compare Little Giant Ladder Systems, LLC v. Tricam Industries, Inc., No. 24-2115 (Fed. Cir. Feb. 5, 2026) (nonprecedential).
• Test rebuttal one: unforeseeability. Objective, at the time of the amendment. Known in the field means foreseeable, even if its suitability for the amended claim's purpose was unknown. See Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 493 F.3d 1368 (Fed. Cir. 2007). Note: If the original claim literally covered the equivalent, foreseeability will fail. See Integrated Technology Corp. v. Rudolph Technologies, Inc., 734 F.3d 1352 (Fed. Cir. 2013). Define the equivalent consistently for infringement and foreseeability under Honeywell International, Inc. v. Hamilton Sundstrand Corp., 523 F.3d 1304 (Fed. Cir. 2008).
• Test rebuttal two: tangentiality. Identify the objectively apparent reason from the record alone, then the way the equivalent departs from the literal claim. Are they different axes? See Ajinomoto Co. v. International Trade Commission, 932 F.3d 1342 (Fed. Cir. 2019) and Eli Lilly & Co. v. Hospira, Inc., 933 F.3d 1320 (Fed. Cir. 2019). Note: An amendment to avoid art containing the equivalent is not tangential. Amending the same element is a powerful, though not conclusive, sign against it. For a patentee's loss on this ground, see Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc., No. 24-1641 (Fed. Cir. May 13, 2026).
• Test rebuttal three: some other reason. Narrow. Unavailable if the equivalent is in the prior art, per Pioneer Magnetics, Inc. v. Micro Linear Corp., 330 F.3d 1352 (Fed. Cir. 2003).
• Review remarks for argument-based estoppel. Test: clear and unmistakable surrender, from the standpoint of a competitor. See Amgen Inc. v. Coherus BioSciences Inc., 931 F.3d 1154 (Fed. Cir. 2019), Pharma Tech Solutions, Inc. v. LifeScan, Inc., 942 F.3d 1372 (Fed. Cir. 2019), and Conoco, Inc. v. Energy & Environmental International, L.C., 460 F.3d 1349 (Fed. Cir. 2006). Note: Statements count even if not needed for allowance and even if not repeated in the last response before allowance.
• Review restriction responses. A restriction requirement does not necessarily raise estoppel, as in UCB, Inc. v. Watson Laboratories Inc., 927 F.3d 1272 (Fed. Cir. 2019).

Red flag: An "allowable if rewritten" indication that the applicant took is the most common hidden estoppel in the file. It looks like nothing happened to the limitation. Under Honeywell the limitation was effectively added by amendment.

Red flag (patentee): A declaration from prosecution counsel explaining the "real" reason for an amendment will not carry a tangentiality argument. The inquiry stays within the record, apart from testimony needed to interpret it.

Phase 3: Disclosure-dedication, vitiation, and foreseeability factors

• Search the specification for the accused alternative. Under Johnson & Johnston Associates Inc. v. R.E. Service Co., 285 F.3d 1046 (Fed. Cir. 2002) (en banc), subject matter disclosed but unclaimed is dedicated to the public.
• Test specificity. Could a skilled reader identify the disclosed, unclaimed subject matter? See PSC Computer Products, Inc. v. Foxconn International, Inc., 355 F.3d 1353 (Fed. Cir. 2004).
• Test "alternative." Is it identified as an alternative to the limitation? See Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., 429 F.3d 1364 (Fed. Cir. 2005). Overlapping "preferably" ranges can qualify under Actelion. Note: A generic formula referenced from another patent did not suffice in Lilly. Eagle Pharmaceuticals Inc. v. Slayback Pharma LLC, 958 F.3d 1171 (Fed. Cir. 2020) shows how a court reads the specification as a whole on this question.
• Write out the vitiation question. What work does the limitation do? If the proposed substitute counts, what is left of it? Use the framing in Akzo Nobel Coatings, Inc. v. Dow Chemical Co., 811 F.3d 1334 (Fed. Cir. 2016). Note: Do not argue that the limitation is simply absent or binary. Deere rejects that. Compare Freedman Seating Co. v. American Seating Co., 420 F.3d 1350 (Fed. Cir. 2005).
• For numeric limits, assess degree. Numbers do not bar equivalents as such, per Adams Respiratory Therapeutics, Inc. v. Perrigo Co., 616 F.3d 1283 (Fed. Cir. 2010), but a theory crossing a real line can fail, as in Moore U.S.A., Inc. v. Standard Register Co., 229 F.3d 1091 (Fed. Cir. 2000).
• Note what the inventor knew. Foreseeability is no bar under Ring & Pinion Service Inc. v. ARB Corp., 743 F.3d 831 (Fed. Cir. 2014), but may be a factor where the patent claims narrowly on its focus, as in Wm. Wrigley Jr. Co. v. Cadbury Adams USA LLC, 683 F.3d 1356 (Fed. Cir. 2012), distinguished in UCB.

Red flag (accused infringer): Telling a court the claim is "binary" invites reversal under Deere, and in Ring & Pinion, on a stipulated record, a district court's vitiation ruling became a directed judgment of infringement.

Phase 4: Ensnarement and go/no-go

• Draft a hypothetical claim broad enough to literally cover the accused product, altering only the limitation in question. See Wilson Sporting Goods Co. v. David Geoffrey & Associates, 904 F.2d 677 (Fed. Cir. 1990). Note: No narrowing limitations, per Jang v. Boston Scientific Corp., 872 F.3d 1275 (Fed. Cir. 2017). The hypothetical must include the literal claim scope and the accused product, per Intendis GmbH v. Glenmark Pharmaceuticals Inc., 822 F.3d 1355 (Fed. Cir. 2016).
• Test it against the known art for anticipation and obviousness.
• Assign burdens. Accused infringer produces art. Patentee persuades. See Interactive Pictures Corp. v. Infinite Pictures, Inc., 274 F.3d 1371 (Fed. Cir. 2001).
• Make the go/no-go call by limitation, using a green, yellow, or red rating, and record the reasons in a privileged memo.
• Run the function, way, result test on paper. With an engineer, state each prong for both the claimed and accused element. If "way" takes more than generalities to fill in, see what evidence exists. Authority: Graver Tank & Mfg. Co. v. Linde Air Products Co., 339 U.S. 605 (1950).
• For chemistry or biology, consider substantial differences. See Mylan Institutional LLC v. Aurobindo Pharma Ltd., 857 F.3d 858 (Fed. Cir. 2017).

Red flag: If the go/no-go relies on "the products look the same," the theory is not ready. The cases disqualify overall similarity by name.

Phase 5: Pleadings

• [P] Plead facts on the limitation in question and meet Rule 11 under Fed. R. Civ. P. 11.
• [D] Evaluate a Rule 12 motion on estoppel or dedication under Fed. R. Civ. P. 12. Authority: Coherus and Eagle. Note: Consider the risk of an order finding the theory plausible, and whether claim construction must come first.
• [D] Plead estoppel and related defenses, and do not list them as abandoned in pretrial filings without thinking through the consequence. Colibri excused such a statement on its facts, but after a real fight.
• [Both] Propose a schedule that addresses when the court will hear Festo, dedication, and ensnarement issues.

Phase 6: Contentions

• [P] Disclose equivalents by limitation, as local patent rules require. Check the forum's current rule and the judge's standing order. Note: Provide function, way, result content where you have it. Do not rely on a catch-all sentence.
• [P] Amend promptly after an adverse construction, on the showing the rules require.
• [D] Challenge boilerplate early, by letter, then by motion.
• [D] Serve non-infringement contentions or an interrogatory response that identifies the differences and the legal limits.
• [D] Serve an interrogatory for the hypothetical claim and for each equivalents theory.

Red flag (patentee): A theory first appearing in an expert report invites a motion to strike. Compare the report line by line to the contentions before service.

Phase 7: Discovery and expert work

• [P] Seek engineering comparisons, test data, and interchangeability statements, including regulatory filings. See Lilly and Graver Tank.
• [P] Take source code and architecture discovery for software claims, and depose engineers about operation at the module level. See VLSI.
• [D] Document the engineering reasons for the design choice through witnesses and existing records.
• [D] Develop inventor knowledge and specification focus. See Wrigley, UCB.
• [D] Collect foreseeability evidence as of the amendment date: publications, products, sales. See Duramed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc., 644 F.3d 1376 (Fed. Cir. 2011).
• [P] Prepare the expert report under Fed. R. Civ. P. 26(a)(2)(B) with particularized testimony and linking argument on each limitation, per Texas Instruments Inc. v. Cypress Semiconductor Corp., 90 F.3d 1558 (Fed. Cir. 1996) and AquaTex Industries, Inc. v. Techniche Solutions, 479 F.3d 1320 (Fed. Cir. 2007). Note: State what function, way, and result are for each side, and why they match. NexStep quotes that requirement from Malta.
• [P] Have someone outside the case read the "way" paragraph and ask whether it explains why, not just whether, the way is the same.
• [D] Prepare a rebuttal report on way, foreseeability, and ensnarement, and test admissibility under Fed. R. Evid. 702. See Expert Disclosure and Daubert Challenge Checklist: A Practical Checklist.
• [Both] Plan expert depositions. Ask the patentee's expert what would not be an equivalent. See Expert Deposition Toolkit: Outline Frameworks, Reliance Material Requests, and Rule 26 Protection Maps.

Red flag (patentee): Testimony that the difference is a "design choice" or a matter of "where an engineer draws this data line" was held insufficient in VLSI. If those words are the heart of the opinion, the verdict is at risk.

Phase 8: Pretrial motions

• [D] Move for summary judgment under Fed. R. Civ. P. 56 in order: estoppel, dedication, vitiation, ensnarement, failure of proof. Authority: Warner-Jenkinson, 520 U.S. at 39 n.8.
• [P] Oppose with record citations for rebuttal, and with expert evidence for foreseeability only, since tangentiality generally stays in the record.
• [P] Serve the hypothetical claim in the form you will defend, with its analysis.
• [D] Move in limine against undisclosed theories and generalized similarity testimony. In Jang the motion failed where reports explained the theory, so be specific.
• [Both] Clarify who decides, and when. Ensnarement and estoppel are for the court, per DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 567 F.3d 1314 (Fed. Cir. 2009). Ask for a bench hearing date.
• [Both] Check Rule 56 standards for vitiation in Deere and DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005 (Fed. Cir. 2006).

Phase 9: Trial

• [P] Walk each limitation at trial with particularized testimony and tie it together in argument. See NexStep, Inc. v. Comcast Cable Communications, LLC, 119 F.4th 1355 (Fed. Cir. 2024). Note: NexStep applied the requirement regardless of how simple the technology seemed. Judge Reyna dissented in part, but the majority controls.
• [Both] Draft instructions stating that equivalence is limitation by limitation, that overall similarity is not the test, and that intent is irrelevant. Warner-Jenkinson.
• [Both] Propose a special verdict by limitation under Fed. R. Civ. P. 49. Warner-Jenkinson, 520 U.S. at 39 n.8, encouraged this.
• [D] Move under Fed. R. Civ. P. 50(a), stating each ground: each missing prong, each legal limit.
• [D] Cross on way, and on differences, using the defendant's engineering reasons.
• [Both] Request a ruling on any reserved Festo or ensnarement issue, and be ready for a post-verdict hearing. Jang approved that timing.

Red flag (accused infringer): A generic "no reasonable jury" Rule 50(a) motion risks forfeiture of the specific arguments you will want on appeal.

Phase 10: Post-trial and appeal

• [D] Renew under Rule 50(b) with the same grounds, within the rule's deadline. See Post-Trial Motion Checklist: A Practical Checklist.
• [P] Defend the verdict on the record: identify the testimony for each prong and each limitation.
• [D] Argue reversal of willfulness and enhancement if liability rests on equivalents, as in Integrated Technology.
• [Both] Map standards of review. Estoppel, rebuttal, dedication, and ensnarement are legal, and reviewed de novo, with fact findings for clear error. Equivalence is reviewed for substantial evidence or, after a bench trial, clear error. Appeals go to the Federal Circuit under 28 U.S.C. § 1295.
• [Both] Check for later developments. This area moves through nonprecedential and precedential opinions alike, so run a current search before filing.

Phase 11: Prosecution fixes (for pending applications)

• Claim disclosed alternatives, or remove them from the specification if truly not intended. Johnson & Johnston. Coordinate with enablement needs under Amgen Inc. v. Sanofi, 598 U.S. 594 (2023). See Section 112 Patent Review Checklist: A Practical Checklist.
• Keep a continuation pending when commercially justified. Johnson & Johnston notes this path and broadening reissue under 35 U.S.C. § 251.
• Weigh "allowable if rewritten" offers against Honeywell. Consider a continuation for the broader subject matter.
• Think through cancellation under Colibri before abandoning a closely related claim.
• Tie remarks to the reference's actual disclosure, and record the objective reason for each amendment. See Responding to a Patent Office Action: A Practical Checklist.
• Avoid limiting characterizations such as "particular," "the invention requires," or "only." Coherus.
• In design applications, file alternatives separately where possible. Pacific Coast.
• Consider appeal for a core limitation instead of accepting a narrowing amendment. Festo treats amendment as a concession.

This checklist is a general working aid and does not replace judgment about a specific patent, record, or forum.

Related Documents

Related Articles

• The Doctrine of Equivalents and Prosecution History Estoppel: When a Patent Reaches Beyond Its Literal Words: the doctrine and leading cases behind each task.
• How to Read a Patent: Claims, Specification, and Prosecution History: the file reading skills Phase 1 assumes.

Related Guides

• Proving or Defeating Infringement Under the Doctrine of Equivalents: A Practical Guide: the same process with sample language and worked examples.
• Preparing for a Markman Hearing: A Practical Guide: the claim construction step that comes first.
• Managing Willfulness Risk After a Patent Notice Letter: A Practical Guide: handling a notice letter that alleges equivalents.

Related Checklists

• Claim Construction Checklist: A Practical Checklist: claim construction tasks.
• Section 112 Patent Review Checklist: A Practical Checklist: disclosure review, from this batch's Section 112 cluster.
• Patent Venue and Transfer Checklist: A Practical Checklist: forum questions, from this batch's venue cluster.
• Privilege Clawback and Rule 502 Checklist: A Practical Checklist: privilege clawback tasks when design history and file materials are produced.
• Responding to a Patent Office Action: A Practical Checklist: office action responses that create or avoid estoppel.
• Expert Disclosure and Daubert Challenge Checklist: A Practical Checklist: expert disclosure and challenge.
• Post-Trial Motion Checklist: A Practical Checklist: Rule 50 and post-trial deadlines.

Related Toolkits

• Doctrine of Equivalents Toolkit: Claim Charts, Estoppel Histories, and Ensnarement Analyses: templates that match the phases above.
• Expert Deposition Toolkit: Outline Frameworks, Reliance Material Requests, and Rule 26 Protection Maps: outlines for the expert depositions in Phase 7.